VisMederi Scientific Committee
VisMederi has its own Scientific Committee
whose purpose is to continually and objectively evaluate VisMederi’s scientific research.
EMANUELE MONTOMOLI (for bio see Board of Directors)
Simonetta Viviani is an independent consultant in vaccines, epidemiology and public health. She collaborates with the Institut National de la Santé et de la Recherche Médical (INSERM) Marseille, France; International Vaccine Institute, Seoul, South Korea; PATH Seattle, USA; the Novartis Vaccines Institute for Global Health (NVGH), Siena, Italy; Takeda Vaccines Zurich, Switzerland; BionetAsia, Bangkog, Thailand. From October 2010 to December 2012 she was Associate VP, Head of the Dengue Clinical Development Program at Sanofi Pasteur. The program which includes large efficacy trials in endemic areas, is in clinical phase IIb/III, and aims to license the first tetravalent live attenuated Dengue vaccine for the prevention of dengue disease. From March 2005 to September 2011, she was Director of Vaccine Development at the Meningitis Vaccine Project (MVP). Created in 2001 with core funding from the Bill & Melinda Gates Foundation, its goal is to eliminate epidemic meningitis in Sub-Saharan Africa through the development and wide spread use of meningococcal conjugate vaccines. In June 2010, a meningococcal A vaccine –MenAfriVac- was prequalified by WHO. Dr Viviani has extensive experience in public health, infectious diseases epidemiology, clinical research, and vaccine development. From September 2002 to February 2005, she has served as clinical research and medical affairs manager for combined pediatric vaccines (DTPHibHBV, MMR) ,Flu and HIV vaccines, at Berna Biotech in Bern, Switzerland, and as medical director at Etna Biotech (Berna Biotech Group) in Catania, Italy. From 1997 to 2002, she was associate director of the clinical research department at Chiron Vaccines in Siena, Italy, where she was in charge of Hib, Hib combined, and meningococcal conjugate vaccines. From 1995 to 1997 she served at the International Agency for Research on Cancer (a WHO agency) as an epidemiologist attached to The Gambia Hepatitis Intervention Study, a large intervention trial aimed to prevent infection, chronic carriage and primary liver cancer in a high risk population by extensive vaccination with Hepatitis B vaccine. Dr Viviani has been a consultant in public health and epidemiology for the Department of Public Health in Florence, Italy, and has collaborated with the Istituto Superiore di Sanità, Rome, Italy on surveillance of communicable and vaccine preventable diseases. She has worked in Public Health and Epidemiology projects in Zimbabwe, Brazil and Guinea Bissau. She has also experience as a family doctor in the rural areas of Tuscany, Italy. Dr. Viviani received a Medicine and Surgery Degree from University of Siena, Italy, as well as postgraduate degrees in Public Health and Laboratory Research. She holds a two-year postgraduate training degree in Field Epidemiology from the CDC, Atlanta, USA, and the Istituto Superiore di Sanità, Rome, Italy. She has served as advisor for the International Agency for Research on Cancer, for the Initiative for Vaccine Research Department at WHO, Geneva, for MSF, Access to Essential Medicines Campaign, Geneva. She has published in the field of public health, epidemiology and vaccinology.
Nigel James Temperton